Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Federica Miglietta(University of Padua), Fabio Girardi(London School of Hygiene & Tropical Medicine), Daniele Generali(University of Trieste), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giancarlo Bisagni, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(University of Ferrara), Luigi Cavanna(University of Pavia), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Aleix Prat(Hospital Clínic de Barcelona), Lorenzo Gianni, Graziella Pinotti(Ospedale di Circolo e Fondazione Macchi), Saverio Cinieri(Ospedale A. Perrino)
Cited by 42
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k